These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Ceramide synthesis regulates T cell activity and GVHD development. Sofi MH; Heinrichs J; Dany M; Nguyen H; Dai M; Bastian D; Schutt S; Wu Y; Daenthanasanmak A; Gencer S; Zivkovic A; Szulc Z; Stark H; Liu C; Chang YJ; Ogretmen B; Yu XZ JCI Insight; 2017 May; 2(10):. PubMed ID: 28515365 [TBL] [Abstract][Full Text] [Related]
3. Icariin protects against acute graft-versus-host disease while preserving graft-versus-leukemia activity after allogeneic hematopoietic stem cell transplantation. Su L; Wei ZF; Pi CC; Qin TX; Song F; Zhang YW; Gao SJ Phytomedicine; 2024 Sep; 132():155901. PubMed ID: 39067193 [TBL] [Abstract][Full Text] [Related]
4. Sphingolipid metabolism in T cell responses after allogeneic hematopoietic cell transplantation. Tian L; Ogretmen B; Chung BY; Yu XZ Front Immunol; 2022; 13():904823. PubMed ID: 36052066 [TBL] [Abstract][Full Text] [Related]
5. Pharmacologic inhibition of PKCα and PKCθ prevents GVHD while preserving GVL activity in mice. Haarberg KM; Li J; Heinrichs J; Wang D; Liu C; Bronk CC; Kaosaard K; Owyang AM; Holland S; Masuda E; Tso K; Blazar BR; Anasetti C; Beg AA; Yu XZ Blood; 2013 Oct; 122(14):2500-11. PubMed ID: 23908466 [TBL] [Abstract][Full Text] [Related]
6. Retention of Donor T Cells in Lymphohematopoietic Tissue and Augmentation of Tissue PD-L1 Protection for Prevention of GVHD While Preserving GVL Activity. Song Q; Nasri U; Nakamura R; Martin PJ; Zeng D Front Immunol; 2022; 13():907673. PubMed ID: 35677056 [TBL] [Abstract][Full Text] [Related]
7. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease. Chang YJ; Zhao XY; Huang XJ Front Immunol; 2018; 9():3041. PubMed ID: 30619371 [TBL] [Abstract][Full Text] [Related]
8. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
9. The Role of Co-stimulatory/Co-inhibitory Signals in Graft-vs.-Host Disease. Kumar S; Leigh ND; Cao X Front Immunol; 2018; 9():3003. PubMed ID: 30627129 [TBL] [Abstract][Full Text] [Related]
10. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. Jones SC; Murphy GF; Korngold R Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217 [TBL] [Abstract][Full Text] [Related]
11. Targeting the Complement Alternative Pathway Permits Graft Versus Leukemia Activity while Preventing Graft Versus Host Disease. Nguyen H; Alawieh A; Bastian D; Kuril S; Dai M; Daenthanasanmak A; Zhang M; Iamsawat S; Schutt SD; Wu Y; Sleiman MM; Shetty A; Atkinson C; Sun S; Varela JC; Tomlinson S; Yu XZ Clin Cancer Res; 2020 Jul; 26(13):3481-3490. PubMed ID: 31919135 [TBL] [Abstract][Full Text] [Related]
12. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration. Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H Front Immunol; 2021; 12():785774. PubMed ID: 34987512 [TBL] [Abstract][Full Text] [Related]
13. Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT. Mammadli M; Huang W; Harris R; Sultana A; Cheng Y; Tong W; Pu J; Gentile T; Dsouza S; Yang Q; Bah A; August A; Karimi M Front Immunol; 2020; 11():593863. PubMed ID: 33324410 [TBL] [Abstract][Full Text] [Related]
14. The impact of regulatory T cells on the graft-versus-leukemia effect. Pacini CP; Soares MVD; Lacerda JF Front Immunol; 2024; 15():1339318. PubMed ID: 38711496 [TBL] [Abstract][Full Text] [Related]
15. Prevention of GVHD without losing GVL effect: windows of opportunity. Zhang P; Chen BJ; Chao NJ Immunol Res; 2011 Apr; 49(1-3):49-55. PubMed ID: 21136200 [TBL] [Abstract][Full Text] [Related]
16. Tolerogenic anti-IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity. Song Q; Wang X; Wu X; Qin H; Li Y; Riggs AD; Martin PJ; Chen YZ; Zeng D Blood; 2021 Apr; 137(16):2243-2255. PubMed ID: 33511398 [TBL] [Abstract][Full Text] [Related]
17. S1P/S1PR1 signaling differentially regulates the allogeneic response of CD4 and CD8 T cells by modulating mitochondrial fission. Tian L; Wu Y; Choi HJ; Sui X; Li X; Sofi MH; Kassir MF; Chen X; Mehrotra S; Ogretmen B; Yu XZ Cell Mol Immunol; 2022 Nov; 19(11):1235-1250. PubMed ID: 36071219 [TBL] [Abstract][Full Text] [Related]
18. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects. Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558 [TBL] [Abstract][Full Text] [Related]
19. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect. Choi J; Cooper ML; Alahmari B; Ritchey J; Collins L; Holt M; DiPersio JF PLoS One; 2014; 9(10):e109799. PubMed ID: 25289677 [TBL] [Abstract][Full Text] [Related]
20. [Immune tolerance induced by cytokines in allogeneic hematopoietic stem cell transplantation]. Chang YJ; Huang XJ Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Apr; 41(2):208-11. PubMed ID: 19377632 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]